Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1017/S2045796024000222 | ||||
| Año | 2024 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Aims The effectiveness and cost-effectiveness of early intervention for psychosis (EIP) services are well established in high-income countries but not in low- and middle-income countries (LMICs). Despite the scarcity of local evidence, several EIP services have been implemented in LMICs. Local evaluations are warranted before adopting speciality models of care in LMICs. We aimed to estimate the cost-effectiveness of implementing EIP services in Brazil.Methods A model-based economic evaluation of EIP services was conducted from the Brazilian healthcare system perspective. A Markov model was developed using a cohort study conducted in Sao Paulo. Cost data were retrieved from local sources. The outcome of interest was the incremental cost-effectiveness ratio (ICER) measured as the incremental costs over the incremental quality-adjusted life-years (QALYs). Sensitivity analyses were performed to test the robustness of the results.Results The study included 357 participants (38% female), with a mean (SD) age of 26 (7.38) years. According to the model, implementing EIP services in Brazil would result in a mean incremental cost of 4,478 Brazilian reals (R$) and a mean incremental benefit of 0.29 QALYs. The resulting ICER of R$ 15,495 (US dollar [USD] 7,640 adjusted for purchase power parity [PPP]) per QALY can be considered cost-effective at a willingness-to-pay threshold of 1 Gross domestic product (GDP) per capita (R$ 18,254; USD 9,000 PPP adjusted). The model results were robust to sensitivity analyses.Conclusions This study supports the economic advantages of implementing EIP services in Brazil. Although cultural adaptations are required, these data suggest EIP services might be cost-effective even in less-resourced countries.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Aceituno, D. | Hombre |
Pontificia Universidad Católica de Chile - Chile
Kings Coll London - Reino Unido Mental Hlth Serv - Chile Hospital Dr Sotero del Rio - Chile King's College London - Reino Unido |
| 2 | Razzouk, D. | - |
Univ Fed Sao Paulo - Brasil
Universidade Federal de São Paulo - Brasil |
| 3 | Jin, H. | - |
Kings Coll London - Reino Unido
King's College London - Reino Unido |
| 4 | Pennington, Mark | Hombre |
Kings Coll London - Reino Unido
King's College London - Reino Unido |
| 5 | Gadelha, Ary | - |
Univ Fed Sao Paulo - Brasil
Universidade Federal de São Paulo - Brasil |
| 6 | Bressan, Rodrigo Affonseca | Hombre |
Univ Fed Sao Paulo - Brasil
Universidade Federal de São Paulo - Brasil |
| 7 | Noto, C. | Hombre |
Univ Fed Sao Paulo - Brasil
Universidade Federal de São Paulo - Brasil |
| 8 | Crossley, Nicolas | Hombre |
Pontificia Universidad Católica de Chile - Chile
|
| 9 | Prina, Matthew A. | Hombre |
Kings Coll London - Reino Unido
Newcastle Univ - Reino Unido Newcastle University - Reino Unido King's College London - Reino Unido |
| Fuente |
|---|
| National Commission for Scientific and Technological Research (CONICYT) |
| Comisión Nacional de Investigación Científica y Tecnológica |
| Eli Lilly and Company |
| H. Lundbeck A/S |
| Janssen-Cilag and Bristol Myers Squibb |
| Agradecimiento |
|---|
| This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. DA was fullyfunded by the National Commission for Scientific and Technological Research(CONICYT) doctoral scholarship, which had no role in the conception or development of this project. |
| NC has received personal fees from Janssen, outside the submitted work. AG has been a consultant and/or advisor to or has received honoraria from Ach\u00E9, Daiichi Sankyo, Torrent, Bayer, Cristalia and Janssen. MP has received personal fees from Merck outside the submitted work. RAB has received research grants from AstraZeneca, Eli Lilly, Lundbeck and Janssen-Cilag for clinical trials and received speaking fees from AstraZeneca, Eli Lilly, Lundbeck, Janssen-Cilag and Bristol Myers Squibb. Other co-authors declare no competing interests. |
| NC has received personal fees from Janssen, outside the submitted work. AG has been a consultant and/or advisor to or has received honoraria from Ach\u00E9, Daiichi Sankyo, Torrent, Bayer, Cristalia and Janssen. MP has received personal fees from Merck outside the submitted work. RAB has received research grants from AstraZeneca, Eli Lilly, Lundbeck and Janssen-Cilag for clinical trials and received speaking fees from AstraZeneca, Eli Lilly, Lundbeck, Janssen-Cilag and Bristol Myers Squibb. Other co-authors declare no competing interests. |